Literature DB >> 12667654

IL-12 dependent/IFN gamma independent expression of CCR5 by myelin-reactive T cells correlates with encephalitogenicity.

Ludmila V Bagaeva1, Lucas P Williams, Benjamin M Segal.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease with similarities to multiple sclerosis (MS). It is induced in mice by the transfer of myelin-reactive T cells. Here we demonstrate that IL-12 stimulates myelin-reactive T cells to up-regulate the beta-chemokine receptor, CCR5, in correlation with the acquisition of central nervous system-infiltrating and encephalitogenic properties. These effects of IL-12 are IFN gamma-independent. The CCR5 ligands, RANTES and MIP-1 alpha, are expressed in the spinal cords of mice at EAE onset. Our results suggest that reagents that block CCR5/beta-chemokine interactions and/or antagonize IL-12 might be useful for treatment of autoimmune demyelination.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667654     DOI: 10.1016/s0165-5728(03)00079-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.

Authors:  Thomas Korn; Jayagopala Reddy; Wenda Gao; Estelle Bettelli; Amit Awasthi; Troels R Petersen; B Thomas Bäckström; Raymond A Sobel; Kai W Wucherpfennig; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Med       Date:  2007-03-25       Impact factor: 53.440

2.  The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.

Authors:  Jia Ni; Yi-Na Zhu; Xiang-Gen Zhong; Yu Ding; Li-Fei Hou; Xian-Kun Tong; Wei Tang; Shiro Ono; Yi-Fu Yang; Jian-Ping Zuo
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration.

Authors:  Daniel May de Oliveira; Enedina Maria Lobato de Oliveira; Merari de Fátima Ramires Ferrari; Patrícia Semedo; Meire Ioshie Hiyane; Marcos Antônio Cenedeze; Alvaro Pacheco-Silva; Niels Olsen Saraiva Câmara; Jean Pierre Schatzmann Peron
Journal:  Inflammopharmacology       Date:  2015-11-11       Impact factor: 4.473

4.  Alloantigen-enhanced accumulation of CCR5+ 'effector' regulatory T cells in the gravid uterus.

Authors:  Marinos Kallikourdis; Kristian G Andersen; Katie A Welch; Alexander G Betz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-29       Impact factor: 11.205

5.  CCR5 controls immune and metabolic functions during Toxoplasma gondii infection.

Authors:  Giuliano Bonfá; Luciana Benevides; Maria do Carmo Souza; Denise Morais Fonseca; Tiago Wilson Patriarca Mineo; Marcos Antônio Rossi; Neide Maria Silva; João Santana Silva; Cristina Ribeiro de Barros Cardoso
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

Authors:  Mark A Kroenke; Thaddeus J Carlson; Anuska V Andjelkovic; Benjamin M Segal
Journal:  J Exp Med       Date:  2008-06-23       Impact factor: 14.307

7.  C-C Chemokine Receptor Type 5 (CCR5)-Mediated Docking of Transferred Tregs Protects Against Early Blood-Brain Barrier Disruption After Stroke.

Authors:  Peiying Li; Long Wang; Yuxi Zhou; Yu Gan; Wen Zhu; Yuguo Xia; Xiaoyan Jiang; Simon Watkins; Alberto Vazquez; Angus W Thomson; Jun Chen; Weifeng Yu; Xiaoming Hu
Journal:  J Am Heart Assoc       Date:  2017-08-02       Impact factor: 5.501

8.  Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.

Authors:  Sumit Mukherjee; Angela Fried; Rahman Hussaini; Richard White; Juliet Baidoo; Sri Yalamanchi; Probal Banerjee
Journal:  J Exp Clin Cancer Res       Date:  2018-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.